Landes Bioscience www.landesbioscience.com

Supplemental Material to:

Scott N. Furlan, Rajakumar Mandraju, Travis Brewer, Kole Roybal, Ty Dale Troutman, Wei Hu, Noah W. Palm, Arun Unni, and Chandrashekhar Pasare

Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors

2014; mAbs 6(1)
http://dx.doi.org/10.4161/mabs.27502

https://www.landesbioscience.com/journals/mabs/article/27502/



Figure S1. Doubling time is not different between modified tumors. A. Tumors were plated at 10^5/mL and counted on day 3. No significant difference was seen in cell turnover rate (replicates of 3 each group). B. No significant difference was seen in the incorporation of ^{3}H thymidine into cell cultures over a 18-hour period.



Figure S2. Culture of DCs with IgG1 Fc expressing tumor does not result in upregulation of activation markers on DCs. Tumors were cultured with BMDCs overnight and DCs were stained to measure upregulation of CD86 (A) or CD40 (B). Heat killed (HK) *Salmonella typhimurium* was used as positive control for DC maturation.



Figure S3. DCs cultured with IgG1 Fc expressing tumor cells do not secrete pro-inflammatory cytokines. Supernatants from BMDCs cultured as described in Figure S2 were assayed for the presence of IL-6 and IL-12 by quantitative ELISA.